Kefeng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kefeng Wang has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Xia Wang
Department of Urology, ShengJing Hospital of China Medical University, Shenyang, China
24 shared publicationsJunhui Hou
Shengjing Hospital of China Medical University
10 shared publicationsYuan Wang
Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China
9 shared publicationsZongwei Lv
Department of Urology, ShengJing Hospital of China Medical University, Shenyang, China
9 shared publicationsChunming Zhu
Shengjing Hospital of China Medical University
8 shared publicationsPeng Su
Medical Research Center, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, People’s Republic of China
7 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-24
Research Progress on Tumor Microenvironment-Responsive siRNA Nanocarriers: Design Strategies, Delivery Efficiency, and Future Perspectives
Gene silencing by RNA interference (RNAi) has emerged as a promising strategy for cancer therapy. Small interfering RNA (siRNA), a class of small regulatory RNAs that recognize and degrade complementary target messenger RNAs (mRNAs) in a sequence-specific manner at the post-transcriptional level, plays a critical role in regulating gene expression. However, the in vivo delivery of siRNA remains a formidable challenge due to its poor physiological stability, susceptibility to enzymatic degradation, inability to efficiently cross cellular membranes, non-specific off-target effects, and immunostimulation. Overcoming these barriers and enhancing the gene silencing efficiency of siRNA in target cells is essential for the clinical translation of RNAi technology. In recent years, tumor microenvironment (TME)-responsive nanocarriers have attracted considerable attention as a strategy to improve siRNA stability, enhance its enrichment and penetration at tumor sites, facilitate cellular uptake, and promote efficient gene silencing. This review comprehensively summarized the design principles and functional characteristics of TME-responsive siRNA delivery nanocarriers, with a focus on five major stimuli: pH, hypoxia, enzymes, glutathione (GSH), and reactive oxygen species (ROS). We critically analyze the advantages and limitations of existing nanocarrier systems, provide comparative insights through summary tables, and discuss future directions including multi-stimuli-responsive systems, combination therapies, and clinical translation challenges. This review aims to provide a systematic framework for understanding and advancing TME-responsive siRNA nanocarriers for tumor therapy.
- 1 September 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-24
Open AccessResearch Progress on Tumor Microenvironment-Responsive siRNA Nanocarriers: Design Strategies, Delivery Efficiency, and Future Perspectives
Gene silencing by RNA interference (RNAi) has emerged as a promising strategy for cancer therapy. Small interfering RNA (siRNA), a class of small regulatory RNAs that recognize and degrade complementary target messenger RNAs (mRNAs) in a sequence-specific manner at the post-transcriptional level, plays a critical role in regulating gene expression. However, the in vivo delivery of siRNA remains a formidable challenge due to its poor physiological stability, susceptibility to enzymatic degradation, inability to efficiently cross cellular membranes, non-specific off-target effects, and immunostimulation. Overcoming these barriers and enhancing the gene silencing efficiency of siRNA in target cells is essential for the clinical translation of RNAi technology. In recent years, tumor microenvironment (TME)-responsive nanocarriers have attracted considerable attention as a strategy to improve siRNA stability, enhance its enrichment and penetration at tumor sites, facilitate cellular uptake, and promote efficient gene silencing. This review comprehensively summarized the design principles and functional characteristics of TME-responsive siRNA delivery nanocarriers, with a focus on five major stimuli: pH, hypoxia, enzymes, glutathione (GSH), and reactive oxygen species (ROS). We critically analyze the advantages and limitations of existing nanocarrier systems, provide comparative insights through summary tables, and discuss future directions including multi-stimuli-responsive systems, combination therapies, and clinical translation challenges. This review aims to provide a systematic framework for understanding and advancing TME-responsive siRNA nanocarriers for tumor therapy.
- Open Access
- 13 August 2026
- Published by Springer Nature in Research Square
AR-Induced RP11-893F2.9 Drives Glutamine-Fatty Acid Metabolic Reprogramming and Malignant Behaviors in ccRCC
Background Clear cell renal cell carcinoma (ccRCC) exhibits a high metabolic plasticity and a poor prognosis. However, the mechanisms of long non-coding RNA (lncRNA) RP11-893F2.9 affect the prognosis of ccRCC through metabolic pathways remains unclear. Methods The role and mechanism of RP11-893F2.9 in ccRCC were investigated by RNA pull-down, actinomycin D assay, western blot, transwell cell migration and invasion, and colony formation assays. Results RP11-893F2.9 promoted the transcription of TMEM92 through HNRNPK, thereby facilitating the growth, migration and invasion of ccRCC cells. RNA-seq revealed enrichment of glutamine metabolism, among which glutamine synthase (GLUL) induction is the most significant. Mechanistically, TMEM92 interacted with Yes-associated protein 1 (YAP1) on the nuclear membrane, facilitating its nuclear translocation and upregulating GLUL. YAP1 knockdown can abolish GLUL induction by RP11-893F2.9. Conclusions RP11-893F2.9, as an AR-activated oncogenic lncRNA, promoted the initiation of ccRCC through the HNRNPK/TMEM92/YAP1/GLUL axis, reprogramed glutamine-fatty acid metabolism and drived the progression of ccRCC.
- 13 August 2026
- Published by Springer Nature in Research Square
Open AccessAR-Induced RP11-893F2.9 Drives Glutamine-Fatty Acid Metabolic Reprogramming and Malignant Behaviors in ccRCC
Background Clear cell renal cell carcinoma (ccRCC) exhibits a high metabolic plasticity and a poor prognosis. However, the mechanisms of long non-coding RNA (lncRNA) RP11-893F2.9 affect the prognosis of ccRCC through metabolic pathways remains unclear. Methods The role and mechanism of RP11-893F2.9 in ccRCC were investigated by RNA pull-down, actinomycin D assay, western blot, transwell cell migration and invasion, and colony formation assays. Results RP11-893F2.9 promoted the transcription of TMEM92 through HNRNPK, thereby facilitating the growth, migration and invasion of ccRCC cells. RNA-seq revealed enrichment of glutamine metabolism, among which glutamine synthase (GLUL) induction is the most significant. Mechanistically, TMEM92 interacted with Yes-associated protein 1 (YAP1) on the nuclear membrane, facilitating its nuclear translocation and upregulating GLUL. YAP1 knockdown can abolish GLUL induction by RP11-893F2.9. Conclusions RP11-893F2.9, as an AR-activated oncogenic lncRNA, promoted the initiation of ccRCC through the HNRNPK/TMEM92/YAP1/GLUL axis, reprogramed glutamine-fatty acid metabolism and drived the progression of ccRCC.
- Open Access
- 23 July 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
Spatial multi-omics analyses of the tumor immune microenvironment: advances and novel therapeutic avenues
The tumor immune microenvironment (TIME) is a spatially organized ecosystem in which the distribution and interaction of cellular and molecular components
- 23 July 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
Open AccessSpatial multi-omics analyses of the tumor immune microenvironment: advances and novel therapeutic avenues
The tumor immune microenvironment (TIME) is a spatially organized ecosystem in which the distribution and interaction of cellular and molecular components
- Open Access
- 27 May 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 225, 105395
Molecular understanding and clinical aspects of adoptive cellular immunotherapy in prostate cancer
- 27 May 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 225, 105395
Open AccessMolecular understanding and clinical aspects of adoptive cellular immunotherapy in prostate cancer
- Open Access
- 20 April 2026
- Published by Springer Nature in Cellular Oncology
- Vol. 49 (3)
Liquid biopsy in the clinical management of tumor of urinary system: current status and future developments
Urinary system tumors are a major threat to human health. However, there is a lack of reliable non-invasive examinations for urinary system tumors. Liquid biopsy is an emerging method for detecting biomarkers in patients in recent years. Its components mainly include circulating tumor cells, circulating tumor DNAs, circulating-free DNAs, circulating-free RNAs, exosomes and tumor educated platelets. Liquid biopsy is considered to be of great significance for the diagnosis, prognosis, treatment monitoring and medication guidance of cancers. The non-invasive characteristics of liquid biopsy significantly improve patients’ compliance and make it possible to collect patient information in real time and continuously. In this review, we selected urinary system tumors as the clinical application subjects of liquid biopsy. We believe that liquid biopsy has great potential value and application prospects in the clinical treatment of urinary system tumors.
- 20 April 2026
- Published by Springer Nature in Cellular Oncology
- Vol. 49 (3)
Open AccessLiquid biopsy in the clinical management of tumor of urinary system: current status and future developments
Urinary system tumors are a major threat to human health. However, there is a lack of reliable non-invasive examinations for urinary system tumors. Liquid biopsy is an emerging method for detecting biomarkers in patients in recent years. Its components mainly include circulating tumor cells, circulating tumor DNAs, circulating-free DNAs, circulating-free RNAs, exosomes and tumor educated platelets. Liquid biopsy is considered to be of great significance for the diagnosis, prognosis, treatment monitoring and medication guidance of cancers. The non-invasive characteristics of liquid biopsy significantly improve patients’ compliance and make it possible to collect patient information in real time and continuously. In this review, we selected urinary system tumors as the clinical application subjects of liquid biopsy. We believe that liquid biopsy has great potential value and application prospects in the clinical treatment of urinary system tumors.
- Open Access
- 29 November 2025
- Published by Wiley in BJUI Compass
- Vol. 6 (12) , e70114
Flexible ureteroscopy with a flexible and navigable suction ureteral access sheath versus mini‐percutaneous nephrolithotomy for 1–2 cm lower pole renal stones: Protocol for an international, multicentre, randomized non‐inferiority trial (FLAME trial)
Background: Lower pole renal stones measuring 1–2 cm remain challenging to treat. While mini‐percutaneous nephrolithotomy (mini‐PCNL) provides high stone‐free rates (SFRs), it carries tract‐related morbidity. Flexible ureteroscopy (f‐URS) is less invasive but limited in SFR. The flexible and navigable suction ureteral access sheath (FANS) has shown promise in improving stone evacuation and intrarenal pressure control. We hypothesize that FANS f‐URS is non‐inferior to mini‐PCNL for patients with 1–2 cm lower pole stones in SFR. Study Design: The FLAME trial is an international, multicentre, randomized, non‐inferiority study directly comparing FANS‐f‐URS with mini‐PCNL in this setting. Endpoints: The primary outcome is immediate SFR within 72 hours on low‐dose CT. Secondary outcomes include SFR at 1 month, operative time, postoperative pain, hospital stay, complications (Clavien–Dindo) and quality‐of‐life changes. Patients and Methods: A total of 640 adults with CT‐confirmed 1–2 cm lower pole renal stones will be randomized 1:1 to undergo FANS‐f‐URS or mini‐PCNL across 20 high‐volume urology centres worldwide. Randomization is centralized and stratified by site. Radiologists and statisticians will remain blinded to allocation. Sample size was calculated assuming an 85% SFR for both arms, an 8.5% non‐inferiority margin, 80% power and 15% attrition. Analyses will follow both intention‐to‐treat and per‐protocol principles. Trial registration: ClinicalTrials.gov NCT07159035.
- 29 November 2025
- Published by Wiley in BJUI Compass
- Vol. 6 (12) , e70114
Open AccessFlexible ureteroscopy with a flexible and navigable suction ureteral access sheath versus mini‐percutaneous nephrolithotomy for 1–2 cm lower pole renal stones: Protocol for an international, multicentre, randomized non‐inferiority trial (FLAME trial)
Background: Lower pole renal stones measuring 1–2 cm remain challenging to treat. While mini‐percutaneous nephrolithotomy (mini‐PCNL) provides high stone‐free rates (SFRs), it carries tract‐related morbidity. Flexible ureteroscopy (f‐URS) is less invasive but limited in SFR. The flexible and navigable suction ureteral access sheath (FANS) has shown promise in improving stone evacuation and intrarenal pressure control. We hypothesize that FANS f‐URS is non‐inferior to mini‐PCNL for patients with 1–2 cm lower pole stones in SFR. Study Design: The FLAME trial is an international, multicentre, randomized, non‐inferiority study directly comparing FANS‐f‐URS with mini‐PCNL in this setting. Endpoints: The primary outcome is immediate SFR within 72 hours on low‐dose CT. Secondary outcomes include SFR at 1 month, operative time, postoperative pain, hospital stay, complications (Clavien–Dindo) and quality‐of‐life changes. Patients and Methods: A total of 640 adults with CT‐confirmed 1–2 cm lower pole renal stones will be randomized 1:1 to undergo FANS‐f‐URS or mini‐PCNL across 20 high‐volume urology centres worldwide. Randomization is centralized and stratified by site. Radiologists and statisticians will remain blinded to allocation. Sample size was calculated assuming an 85% SFR for both arms, an 8.5% non‐inferiority margin, 80% power and 15% attrition. Analyses will follow both intention‐to‐treat and per‐protocol principles. Trial registration: ClinicalTrials.gov NCT07159035.
- Open Access
- 17 June 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-17
m6A reader IGF2BP2-stabilized lncRNA LHX1-DT inhibits renal cell carcinoma (RCC) cell proliferation and invasion by sponging miR-590-5p
N6-methyladenosine (m6A) has been established as a critical regulator in various human cancers. However, the role of m6A modification in renal cell carcinoma (RCC) and its interaction with long non-coding RNA LHX1-DT (LHX1-DT) remains unclear. Differentially expressed lncRNAs and m6A levels were identified through microarray analysis. The interaction between IGF2BP2 and LHX1-DT was examined via RNA immunoprecipitation and luciferase reporter assays. LHX1-DT expression was found to be downregulated in RCC tissues, and reduced expression of LHX1-DT was associated with poor overall survival in RCC patients. Functional assays demonstrated that overexpression of LHX1-DT significantly inhibited RCC cell proliferation and invasion. The m6A reader protein IGF2BP2, mediated by METTL14, recognized the m6A modification site on LHX1-DT and promoted its stability. Additionally, LHX1-DT acted as a competing endogenous RNA (ceRNA) by sponging miR-590-5p, which in turn downregulated PDCD4, thereby inhibiting RCC cell proliferation and invasion. LHX1-DT serves as an independent prognostic biomarker for RCC, and the IGF2BP2/LHX1-DT/miR-590-5p/PDCD4 axis represents a novel therapeutic target for RCC progression.
- 17 June 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-17
Open Accessm6A reader IGF2BP2-stabilized lncRNA LHX1-DT inhibits renal cell carcinoma (RCC) cell proliferation and invasion by sponging miR-590-5p
N6-methyladenosine (m6A) has been established as a critical regulator in various human cancers. However, the role of m6A modification in renal cell carcinoma (RCC) and its interaction with long non-coding RNA LHX1-DT (LHX1-DT) remains unclear. Differentially expressed lncRNAs and m6A levels were identified through microarray analysis. The interaction between IGF2BP2 and LHX1-DT was examined via RNA immunoprecipitation and luciferase reporter assays. LHX1-DT expression was found to be downregulated in RCC tissues, and reduced expression of LHX1-DT was associated with poor overall survival in RCC patients. Functional assays demonstrated that overexpression of LHX1-DT significantly inhibited RCC cell proliferation and invasion. The m6A reader protein IGF2BP2, mediated by METTL14, recognized the m6A modification site on LHX1-DT and promoted its stability. Additionally, LHX1-DT acted as a competing endogenous RNA (ceRNA) by sponging miR-590-5p, which in turn downregulated PDCD4, thereby inhibiting RCC cell proliferation and invasion. LHX1-DT serves as an independent prognostic biomarker for RCC, and the IGF2BP2/LHX1-DT/miR-590-5p/PDCD4 axis represents a novel therapeutic target for RCC progression.
- Open Access
- 7 April 2025
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (4) , e70299
The role of cancer‐associated fibroblasts in the tumour microenvironment of urinary system
Urological tumours are a type of neoplasms that significantly jeopardise human life and wellbeing. Cancer‐associated fibroblasts (CAFs), serving as the primary component of the stromal cellular milieu, form a diverse cellular cohort that exerts substantial influence on tumourigenesis and tumour progression. In this review, we summarised the literatures regarding the functions of CAFs in the urinary tumour microenvironment (TME). We primarily examined the multifaceted activities of CAFs in the TME of urological system tumours, including inhibiting tumour immunity, remodelling the extracellular matrix, promoting tumour growth, metastasis, drug resistance and their clinical applications. We also discussed potential future directions for leveraging artificial intelligence in CAFs research.Key points: The interaction of CAFs with various cell secretory factors in the TME of urological tumors. The application of CAFs in diagnosis, treatment and prognosis of urological tumors.
- 7 April 2025
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (4) , e70299
Open AccessThe role of cancer‐associated fibroblasts in the tumour microenvironment of urinary system
Urological tumours are a type of neoplasms that significantly jeopardise human life and wellbeing. Cancer‐associated fibroblasts (CAFs), serving as the primary component of the stromal cellular milieu, form a diverse cellular cohort that exerts substantial influence on tumourigenesis and tumour progression. In this review, we summarised the literatures regarding the functions of CAFs in the urinary tumour microenvironment (TME). We primarily examined the multifaceted activities of CAFs in the TME of urological system tumours, including inhibiting tumour immunity, remodelling the extracellular matrix, promoting tumour growth, metastasis, drug resistance and their clinical applications. We also discussed potential future directions for leveraging artificial intelligence in CAFs research.Key points: The interaction of CAFs with various cell secretory factors in the TME of urological tumors. The application of CAFs in diagnosis, treatment and prognosis of urological tumors.
- Open Access
- 14 March 2025
- Published by Springer Nature in Research Square
Baicalein exerts an anti-tumor role through AKT/Survivin signaling pathway in clear cell renal cell carcinoma
Background: Recently, baicalein has been shown to influence tumor progression by affecting cell growth, apoptosis, autophagy, and epithelial-mesenchymal transition (EMT), et al. However, the application of baicalein in clear cell renal cell carcinoma (ccRCC) has not been reported. Methods:Bioinformatics methods were used to obtain the main targets of baicalein. The ccRCC targets were acquired through transcriptome sequencing datasets. The core targets of drug interaction with ccRCC were further gained through protein-protein interaction (PPI) network. The main cells of the core targets were identified by single-cell analysis. Results: By constructing the PPI network, 49 core drug-disease interaction targets were obtained. The Kyoto Encyclopedia of Genes and Genomes analysis showed significant enrichment of PI3K/AKT signaling pathway and apoptosis pathway. The results of CCK8 assay and colony formation assay revealed that baicalein could inhibit the proliferation of ccRCC cells in a dose-dependent manner. The results of wound healing and transwell assay indicated that baicalein could inhibit the migration of ccRCC cells. Flow cytometry verified that baicalein could promote apoptosis of ccRCC cells. Finally, western blot assay confirmed that baicalein could affect the tumorigenesis by regulating the expression of AKT/p-AKT expression. Conclusions: Our experiments demonstrated that baicalein could affect the apoptosis of ccRCC cells through AKT/p-AKT/Survivin pathway, and regulate the EMT process through the expression of E-cadherin, N-cadherin, and Vimentine. Baicalein was a traditional Chinese herbal monomer which can effectively inhibit the progression of ccRCC.
- 14 March 2025
- Published by Springer Nature in Research Square
Open AccessBaicalein exerts an anti-tumor role through AKT/Survivin signaling pathway in clear cell renal cell carcinoma
Background: Recently, baicalein has been shown to influence tumor progression by affecting cell growth, apoptosis, autophagy, and epithelial-mesenchymal transition (EMT), et al. However, the application of baicalein in clear cell renal cell carcinoma (ccRCC) has not been reported. Methods:Bioinformatics methods were used to obtain the main targets of baicalein. The ccRCC targets were acquired through transcriptome sequencing datasets. The core targets of drug interaction with ccRCC were further gained through protein-protein interaction (PPI) network. The main cells of the core targets were identified by single-cell analysis. Results: By constructing the PPI network, 49 core drug-disease interaction targets were obtained. The Kyoto Encyclopedia of Genes and Genomes analysis showed significant enrichment of PI3K/AKT signaling pathway and apoptosis pathway. The results of CCK8 assay and colony formation assay revealed that baicalein could inhibit the proliferation of ccRCC cells in a dose-dependent manner. The results of wound healing and transwell assay indicated that baicalein could inhibit the migration of ccRCC cells. Flow cytometry verified that baicalein could promote apoptosis of ccRCC cells. Finally, western blot assay confirmed that baicalein could affect the tumorigenesis by regulating the expression of AKT/p-AKT expression. Conclusions: Our experiments demonstrated that baicalein could affect the apoptosis of ccRCC cells through AKT/p-AKT/Survivin pathway, and regulate the EMT process through the expression of E-cadherin, N-cadherin, and Vimentine. Baicalein was a traditional Chinese herbal monomer which can effectively inhibit the progression of ccRCC.
- Open Access
- 22 August 2024
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 43 (1) , 1-16
Molecular understanding and clinical aspects of tumor-associated macrophages in the immunotherapy of renal cell carcinoma
Renal cell carcinoma (RCC) is one of the most common tumors that afflicts the urinary system, accounting for 90–95% of kidney cancer cases. Although its incidence has increased over the past decades, its pathogenesis is still unclear. Tumor-associated macrophages (TAMs) are the most prominent immune cells in the tumor microenvironment (TME), comprising more than 50% of the tumor volume. By interacting with cancer cells, TAMs can be polarized into two distinct phenotypes, M1-type and M2-type TAMs. In the TME, M2-type TAMs, which are known to promote tumorigenesis, are more abundant than M1-type TAMs, which are known to suppress tumor growth. This ratio of M1 to M2 TAMs can create an immunosuppressive environment that contributes to tumor cell progression and survival. This review focused on the role of TAMs in RCC, including their polarization, impacts on tumor proliferation, angiogenesis, invasion, migration, drug resistance, and immunosuppression. In addition, we discussed the potential of targeting TAMs for clinical therapy in RCC. A deeper understanding of the molecular biology of TAMs is essential for exploring innovative therapeutic strategies for the treatment of RCC.
- 22 August 2024
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 43 (1) , 1-16
Open AccessMolecular understanding and clinical aspects of tumor-associated macrophages in the immunotherapy of renal cell carcinoma
Renal cell carcinoma (RCC) is one of the most common tumors that afflicts the urinary system, accounting for 90–95% of kidney cancer cases. Although its incidence has increased over the past decades, its pathogenesis is still unclear. Tumor-associated macrophages (TAMs) are the most prominent immune cells in the tumor microenvironment (TME), comprising more than 50% of the tumor volume. By interacting with cancer cells, TAMs can be polarized into two distinct phenotypes, M1-type and M2-type TAMs. In the TME, M2-type TAMs, which are known to promote tumorigenesis, are more abundant than M1-type TAMs, which are known to suppress tumor growth. This ratio of M1 to M2 TAMs can create an immunosuppressive environment that contributes to tumor cell progression and survival. This review focused on the role of TAMs in RCC, including their polarization, impacts on tumor proliferation, angiogenesis, invasion, migration, drug resistance, and immunosuppression. In addition, we discussed the potential of targeting TAMs for clinical therapy in RCC. A deeper understanding of the molecular biology of TAMs is essential for exploring innovative therapeutic strategies for the treatment of RCC.